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Abstract
Background: There is paucity of data concerning the optimal revascularization in patients with mul-
tivessel coronary artery disease (CAD) presenting non-ST-segment elevation acute coronary syndrome 
(NSTE-ACS). The aim was to evaluate long-term outcomes of patients with multivessel CAD presenting 
NSTE-ACS depending on the management after coronary angiography.
Methods: 3,166 patients with NSTE-ACS hospitalized between 2006 and 2014 were screened. After ex-
clusions, 1,342 patients were enrolled with multivessel CAD and were divided depending on their man-
agement after coronary angiography; the medical-only therapy group (n = 91), the percutaneous coronary 
intervention (PCI) group (n = 1,122), the coronary artery bypass grafting (CABG) group (n = 129).  
Propensity scores matching was used to adjust for differences in patient baseline characteristics.
Results: After propensity score analysis,  273 well-matched patients were chosen. Both before and 
after matching, patients treated with a medical-only therapy were burdened with the highest percentage 
of  24-month all-cause death and  non-fatal MI in comparison to PCI and CABG groups, respectively. 
In the CABG group, ACS-driven revascularization rate was lowest. In the overall population, PCI  
(HR 0.33; 95% CI 0.20–0.53; p < 0.0001) and CABG (HR 0.54; 95% CI 0.31–0.93; p = 0.028) were 
independent factors associated with favorable 24-month prognosis. However, in a matched population 
only PCI was an independent predictor of long-term prognosis with a 63% decrease of 24-month mortal-
ity (HR 0.37; 95% CI 0.19–0.69; p = 0.0020). 
Conclusions: In patients with multivessel CAD presenting with NSTE-ACS, medical-only man-
agement is related with adverse long-term prognosis in contrast to revascularization, which reduces 
24-month mortality, especially among patients undergoing percutaneous intervention. Performance 
of PCI is an independent factor for improving long-term prognosis. (Cardiol J 2019; 26, 2: 157–168)
Key words: non-ST-elevation myocardial infarction, percutaneous coronary intervention, 
coronary bypass grafts, multivessel coronary artery disease, long-term outcomes
Introduction
Multivessel coronary artery disease (CAD) 
is observed in 35–70% cases of non-ST-segment 
elevation acute coronary syndromes (NSTE-ACS) 
[1–4]. Moreover, multivessel CAD is one of the 
most common causes of higher risk for cardiovas-
cular morbidity and mortality in this population [5, 
6]. Although, an early invasive approach in patients 
with moderate-to-high risk is recommended, man-
agement of patients with confirmed multivessel 
CAD is controversial [7–9]. The guidelines suggest 
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that the artery responsible for ischemia should 
be treated first [9, 10]. However, in the case of 
multivessel CAD, subsequent treatment strategies 
include percutaneous coronary intervention, (PCI), 
coronary artery bypass grafting (CABG) or medical-
only therapy. Choice of treatment modality, com-
pleteness and optimal timing of revascularization 
(one- or multi-stage) of remaining lesions remains 
a contentious issue. Lack of detailed recommenda-
tions regarding optimal revascularization strategy is 
caused by a paucity of randomized trials and a small 
number of retrospective studies [11–14].
The main purpose of this study was to evaluate 
long-term outcomes of patients with multives-
sel CAD presenting NSTE-ACS. Therefore, an 
analysis was  performed of clinical and angiographic 
status and the impact of treatment management 
on the incidence of 24-month all-caused death and 
identification of independent risk factors influenc-
ing the prognosis.
Methods
Study design
In this single-center prospective study, regis-
try data of 3,166 consecutive patients with NSTE-
-ACS hospitalized from January 2006 to December 
2014 were screened. Patients without invasive 
diagnostics during the acute phase of NSTE-ACS, 
with a history of CABG, with non-obstructive or 
single-vessel CAD were excluded from further 
analysis. Enrolled patients were divided into three 
groups depending on treatment after coronary an-
giography: medical-only therapy group — patients 
qualified for medical conservative treatment; PCI 
group — patients treated with PCI in the first in-
stance; CABG group — patients treated CABG in 
the first instance.
The diagnosis and treatment of the study 
population were conducted in a highlyspecialized 
cardiology center with cardiac surgery facilities. 
Management of patients was based on current 
recommendations of the European Society of 
Cardiology (ESC) [9, 15, 16]. All patients qualified 
for invasive strategy have received acetylsalicylic 
acid and weight-adjusted unfractionated heparin. 
Coronary angiography was performed routinely 
from radial or femoral artery access depending on 
operator discretion. During invasive diagnostics, 
standard guidewires and catheters were used. 
After coronary angiography all decisions regard-
ing method of treatment (medical management, 
PCI, CABG), in particular the use of stents, type 
of stent, type of cardiac surgery operation, number 
of grafts, periprocedural use of anticoagulants and 
antiplatelet drugs, and further revascularization 
were dependent on the decision of the operator or 
the Heart Team. In cases of recurrence of steno-
cardial symptoms associated with ST-T deviations, 
urgent coronary angiography was performed. 
Dual-antiplatelet therapy was endorsed for at 
least 12 months subsequent to hospitalization. 
Others drugs were prescribed in accordance with 
the ESC Guidelines [9, 15, 16]. The next stage 
of revascularization was routinely planned up to 
3 months after index hospitalization. The adopted 
method of division into groups allowed the hybrid 
revascularization approach.
Data collecting and acquisition
Demographic, clinical and echocardiographic 
data regarding index hospital stay were collected 
by physicians and uploaded to the institutional 
database. Additionally, a retrospective analysis 
of coronary angiography, morphology and loca-
tion of coronary artery lesions in all patients was 
conducted. 24-month follow-up data, including spe-
cific date of death, non-fatal myocardial infarction 
(MI) and acute coronary syndrome (ACS) driven 
revascularization was obtained from the official 
registry of the National Health Fund, guaranteeing 
complete data collection. Detailed data from further 
hospitalization planned within 3 month after dis-
charge was also implemented to the institutional 
database. Follow-up data was available for whole 
study population. 
This study was granted permission from the 
Institutional Review Board and University Bioeth-
ics Committee, and is in accordance with the ethi-
cal standards laid down in the 1964 Declaration of 
Helsinki and its later amendments [17].
Definitions and endpoints
NSTE-ACS was diagnosed on the basis of 
(1) clinical presentation: i) prolonged (> 20 min) 
anginal pain at rest, ii) new onset (de novo) angina 
(Class II or III of the Classification of the Canadian 
Cardiovascular Society), iii) recent destabilization 
of previously stable angina with at least Canadian 
Cardiovascular Society Class III angina charac-
teristics (crescendo angina), (2) the absence of 
ST-segment elevation consistent with an infarction 
of ≥ 2 mm in contiguous chest leads, ST-segment 
elevation of ≥ 1 mm in 2 or more standard leads, 
or a new left bundle branch block and (3) af-
ter exclusion of alternative causes of chest pain 
[9, 15, 16]. Subsequently, patients with NSTE-ACS 
were classified as having unstable angina (UA) or 
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non-ST-segment elevation myocardial infarction 
(NSTEMI) based on measured values of mark-
ers of myocardial necrosis in accordance with the 
Universal Definition of Myocardial Infarction [18]. 
Since 2009 high-sensitive cardiac troponin T was 
measured in the institutional central laboratory. 
Multivessel CAD was defined as hemodynami-
cally significant stenosis in left main (LM) or in 
at least two major epicardial territories or in their 
major branches (left anterior descending [LAD], 
left circumflex or right coronary artery system) 
with a diameter ≥ 2.0 mm as determined by visual 
assessment with on-line quantitative coronary 
angiography using orthogonal views [19]. As hemo-
dynamically significant ≥ 50% diameter stenosis 
in LM or proximal segment of LAD and ≥ 70% 
diameter stenosis in other segments were also 
considered. Angiographic success was defined as 
the achievement of a minimum stenosis diameter 
reduction to < 20% in the presence of TIMI flow 
3 grade.
The primary outcome measure included the 
occurrence of 24-month all-cause death. The 
secondary endpoints were non-fatal recurrent 
myocardial infarction (MI), ACS-driven unplanned 
revascularization and stroke at 24 months. Non-
fatal MI was defined as an ischemic event that met 
ESC/American College of Cardiology criteria for MI 
and were clearly clinically separate from the base-
line ACS at the time of admission [18]. ACS-driven 
repeat revascularization was defined as additional, 
unplanned angioplasty or CABG, performed as 
an urgent procedure because of acute ischemic 
symptoms [19]. Stroke was defined as an ischemic 
event that was in accordance with European Stroke 
Organization guidelines [20].
Statistical analysis
Statistical analysis included a comparison of 
baseline, angiographic and procedural character-
istics, and the incidence of cardiovascular events 
during 24-month follow-up. The analyzed vari-
ables are expressed as numbers and percentages. 
The distribution normality was verified using the 
Shapiro-Wilk test. Continuous variables were 
summarized using arithmetic mean with standard 
deviation (SD) for data following normal distribu-
tion or median with quartile 1 and 3 (Q1–Q3) for 
data demonstrating non-normal distribution. The 
analysis of variance (ANOVA) test for comparison 
of continuous parameters with normal distribu-
tion was performed, whereas the Kruskal-Wallis 
ANOVA rank test for parameters with non-normal 
distribution was used. Categorical variables were 
compared using the c2 test with the Pearson’s 
modification or with the Yates correction if the 
expected number of observations was less than 5. 
All-cause mortality, non-fatal MI, ACS-driven re-
vascularization and stroke in 24-month follow-up 
for all patients were analyzed using the Kaplan-
Meier method with log-rank test. To minimize 
the confounding impact of risk factors affecting 
24-month outcomes. A propensity score analysis 
was performed to adjust for differences in patient 
baseline characteristics. First, logistic regression 
was performed to score all patients according to 
treatment (medical-only therapy vs. PCI; medical-
only therapy vs. CABG), used as covariates the 
clinical and procedural parameters that were 
clinically relevant for the endpoint: age (years), 
gender (male/female), diabetes mellitus, prior MI, 
ST-segment deviation, left ventricular ejection 
fraction, triple-vessel CAD and chronic total occlu-
sion. In the next stage, analyses were performed 
on  two matched groups (medical-only therapy vs. 
PCI and medical-only therapy vs. CABG), stratified 
into pairs to account for propensity score matching. 
The nearest neighbor matching was used. Both 
before and after propensity score matching, the 
Cox proportional hazards model was performed. 
Factors were analyzed by stepwise backward elimi-
nation (p < 0.3 for entry into the model, p < 0.05 
to remain in the model). The independence of fac-
tors were verified by interactions testing. Results 
were summarized as hazard ratio (HR) with 95% 
confidence interval (CI). A two-sided p-value 
< 0.05 was considered significant. The STATIS-
TICA 10 software (StatSoft Inc., Tulsa, Oklahoma) 
was used for all calculations.
Results
During an observation period from 2006 to 
2014, a total of 3,166 patients with NSTE-ACS 
were analyzed (Fig. 1). After exclusions, among 
patients with multivessel CAD, in 91 patients 
medical-only treatment was implemented while 
in the remaining 1,251 patients  revascularization 
was performed. Of these, 1,122 patients under-
went PCI and 129 patients CABG. The average 
age of the study population was 66.9 ± 10.9 years, 
68.0% were males, and the definitive diagnosis of 
MI was recognized in 64.2%. Baseline character-
istics and results of additional testing of the study 
groups are summarized in Table 1. In general, the 
medical-only treatment group had the worst clini-
cal profile with the highest GRACE score results. 
The post-hoc analysis showed that patients from 
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the PCI group in comparison with CABG group 
had significantly more frequently final NSTEMI 
diagnosis, higher troponin T (p < 0.0001), glucose 
level on admission (p = 0.0029), lower level of left 
ventricular ejection fraction (p = 0.0033), while 
less often arterial hypertension (p = 0.012) and 
peripheral artery disease (p = 0.026). Overall, the 
GRACE Risk in PCI in comparison with CABG 
group was higher (p = 0.036). Angiographic and 
procedural characteristics  are presented in Table 2. 
Patients qualified to medical-only treatment and 
to cardiac surgery demonstrated more advanced 
severity of coronary disease when compared to 
patients treated with PCI. Overall, the rate of 
patients undergoing hybrid revascularization was 
5.7% (6.1% in PCI group and 2.3% in CABG group). 
Approximately half of patients from CABG group 
underwent complete anatomic revascularization 
after 6-month from discharge, whereas in PCI 
group this proportion accounted for approximately 
one-third of patients.
After propensity score matching of the study 
population group, 273 patients were selected. 
Patients in medical-only therapy and PCI groups 
had lower left ventricular ejection fraction in 
comparison to CABG patients. Also, the overall 
GRACE score was higher in medical-only therapy 
than in CABG group. Left main disease was more 
frequent in medical-only therapy and CABG than in 
PCI group. The other differences in baseline clini-
cal characteristics and angiography were reduced 
with nonsignificant p value. 
Table 3 contains the in-hospital, early and 
long-term outcomes. Kaplan-Meier curves for 
Figure 1. Study design; CABG — coronary artery bypass 
grafting; CAD — coronary artery disease; NSTE-ACS — 
non-ST-segment elevation acute coronary syndromes; 
PCI — percutaneous coronary intervention.
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study groups are presented in Figure 2. A total 
percentage of 12- and 24-month all-cause death in 
the overall study population was 12.8% and 18.7%, 
respectively. Patients treated with medical-only 
therapy were burdened with the highest percent-
age of 12- and 24-month all-cause death. Moreover, 
the highest rate of non-fatal MI in those patients 
was observed. In the CABG group, ACS-driven 
revascularization rate was the lowest. After pro-
pensity score matching, there were no differences 
in the incidence of 12-month events between 
analyzed groups. At 24 months, the medical-only 
treatment was associated with the highest occur-
rence of all-cause death and non-fatal MI, while 
in PCI group had the highest rate of ACS-driven 
revascularization.
The Cox proportional hazards model before 
(A) and after (B) propensity score matching is 
presented in Figure 3. In the study population, PCI 
and CABG were independent factors of improved 
24-month prognosis. However, in matched popu-
lation only PCI was an independent predictor of 
24-month prognosis with reduction of 24-month 
mortality by 63%. 
Discussion
The vast majority of contemporary studies 
comparing treatment strategy of multivessel CAD 
were performed in patients with stable angina [21–
–23]. Multicenter, randomized trials comparing PCI 
to CABG, encompassed from 13% to 91% patients 
with UA or recent MI [22]. In NSTE-ACS popula-
tion, except for one single-center trial comparing 
an optimal timing of staged multivessel interven-
tion [13], to date no prospective randomized clinical 
trial has been conducted to evaluate the treatment 
modality of multivessel CAD. Moreover, there is 
only a limited number of data obtained from one su-
banalysis of randomized trial and few retrospective 
studies [11, 12, 14, 24–26]. The optimal treatment 
method in overall as well as in particular subgroups 
of patients with NSTE-ACS is unclear. Therefore, 
the decision to conduct an assessment of treatment 
of multivessel CAD in real-world patients present-
ing with NSTE-ACS was undertaken.
In the present study comprising 3,166 patients 
with NSTE-ACS, the percentage of multivessel 
CAD without prior CABG was more than 42%. 
The present results are similar to those previ-
ously reported for NSTE-ACS patients, where 
occurrence of multivessel CAD ranged from 35% 
to 70% [1–4]. Also, baseline clinical and angio-
graphic characteristics of the patients appears to be Ta
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Figure 2. Kaplan-Meier survival curves for 24-month rates of all-cause death (A), non-fatal myocardial infarction (B) 
acute coronary syndromes-driven revascularization (C) and stroke (D) in study groups; CABG — coronary artery by-
pass grafting; PCI — percutaneous coronary intervention.
Figure 3. Forest plot of independent predictors of 24-month all-cause mortality in the study population (A) and in 
a matched cohort (B); CAD — coronary artery disease; CI — confidence interval; LVEF — left ventrucular ejection 
fraction; PCI — percutaneous coronary intervention.
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comparable to other registries, this demonstrates 
a good reflection of the present patients to the 
general population of NSTE-ACS [11, 12, 25]. In 
this study, patients treated invasively constituted 
less than 84%, surgical treatment was performed 
in 10% and in remaining patients the medical-only 
treatment was implemented. Gierlotka et al. [27] 
found that the rates of revascularization among 
Polish patients with NSTEMI shows an upward 
trend with contemporary use of PCI in more than 
55%, and CABG in more than 10% patients. In su-
banalysis of ACUITY trial, designed to compare two 
methods of revascularization in multivessel CAD, 
patients undergoing PCI accounted for 78%, while 
CABG group consisted of 22% of study population 
[14]. Also, in other studies PCI was the most com-
mon method of treatment for multivessel CAD in 
NSTE-ACS [24–26, 28].
Early and long-term outcomes in the present 
analysis have shown that patients treated conserva-
tively after coronary angiography are characterized 
by the worst prognosis. This result is intelligible in 
terms of current state of the art of management in 
NSTE-ACS [9, 29]. Qualification for medical-only 
treatment after diagnostic coronary angiography 
may be result of anatomical infeasibility of revas-
cularization (i.e. rates of chronic total occlusions) 
and/or severe clinical status of patients [30]. The 
long-term outcomes were similar in PCI and CABG 
groups, except for higher frequency of ACS-driven 
revascularization in PCI group. There were no 
differences in the occurrence of stroke. In virtu-
ally all clinical trials, CABG was associated with 
higher rates of stroke in comparison with PCI [31]. 
The results of ACUITY trial showed that invasive 
treatment may be associated with lower incidence 
of non-fatal periprocedural MI, stroke and major 
bleeding, while CABG with lower occurrence of 
recurrent ischemia [14]. After propensity score 
matching analysis, early and long-term mortality 
in patients treated with PCI was similar to CABG 
group. However, an insignificant, but numerically 
higher incidence of the composite endpoint (25% 
vs. 19%; p = 0.053) was observed, which was 
mainly driven by a meaningfully higher percent-
age of unplanned repeat revascularization (12% 
vs. 0.2%; p < 0.001). A similar correlation dem-
onstrating comparable efficacy of PCI and CABG 
in NSTE-ACS has been demonstrated in the is-
sue of unprotected LM coronary artery [32, 33], 
a proximal segment of LAD [34] and in patients with 
multivessel CAD and diabetes mellitus [35]. On 
the other hand, in the MILESTONE Registry, im-
mediate PCI was associated with lower long-term 
mortality risk compared with surgical revascu-
larization, especially in subgroups at high clinical 
risk [26]. Importantly in the present study, after 
adjusting for factors from baseline and angiographic 
characteristics, the performance of PCI was an 
independent predictor of improved prognosis in 
24-month follow-up. These meaningful outcomes 
are in accordance with the expert opinions that 
after identification a culprit vessel during coro-
nary angiography, PCI should be the first choice 
procedure in the treatment of NSTE-ACS. After 
PCI of culprit vessel, further decisions regarding 
revascularization of non-ischemia-related vessels 
should be carried out after Heart Team consultation 
or based on the locally adopted proceedings proto-
cols. PCI should also be recommended in the case 
of an occurrence of multiple lesions responsible for 
the manifestation of NSTE-ACS [36].
It is well documented that most benefits from 
an invasive strategy and subsequent PCI refers 
to patients undergoing intervention respectively 
in 24 (high risk) or 72 (moderate risk) hours from 
admission to hospital [9]. However, another impor-
tant issue in multivessel CAD is optimal timing of 
revascularization in vessels other than the culprit 
vessel. There is  widespread agreement of experts 
that in stable clinical status after intervention in 
the artery responsible for NSTE-ACS, treatment 
decisions regarding other stenosed vessels may 
be based on recommendations for stable CAD. 
In patients with severe, multivessel CAD, the 
preferred modality of treatment recommended by 
ESC is CABG. Nevertheless, outcomes of SYNTAX 
and EXCEL trials indicate that, the use of PCI as 
an alternative to cardiac surgery may be applied in 
patients with low-to-moderate SYNTAX score [21, 
37, 38]. In the present study, more than a quarter 
of patients in PCI group was scheduled for the next 
stage of revascularization after discharge, whereas 
in 62% patients of CABG group, the operation was 
performed during further hospitalization. The 
results of retrospective studies and their meta-
analyzes suggest that performing multivessel PCI 
during index hospitalization in patients presenting 
with NSTE-ACS may improve a long-term prog-
nosis [11, 12]. Sardella et al. [13] in SMILE Trial 
has demonstrated that one-stage multivessel PCI 
is superior to postponed intervention. Due to 
a lack of randomized trials, optimal time frames 
of performance of CABG in NSTE-ACS patients 
are unclear. In accordance with expert consensus 
and results of clinical registries, CABG should 
be implemented after 48–72 hours after perfor-
mance of culprit vessel PCI, except for patients 
166 www.cardiologyjournal.org
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with ongoing myocardial ischemia, hemodynamic 
instability or very-high-risk coronary anatomy 
when there should be no delay with an operation 
[39]. However, the final decision should be taken 
by the Heart Team on the basis of clinical status 
and severity of CAD.
The previous data indicate that more complete 
revascularization of multivessel CAD may be as-
sociated with lower frequency of adverse events, 
particularly repeat urgent revascularization when 
compared to treatment limited only to the artery 
responsible for NSTE-ACS manifestation [11, 
12]. Herein was found that the percentage of pa-
tients who underwent complete revascularization 
within 6 months after diagnosis of NSTE-ACS was 
more than 34% in PCI group and more than 50% 
in the CABG group. Similarly, a meta-analysis of 
retrospective studies proved that performance of 
multivessel PCI results in a reduction of long-term 
composite endpoint, mainly due to lower incidence 
of ischemia-driven revascularization. Data above 
indicate the need for complete revascularization 
in patients with multivessel CAD, if anatomical 
factors and the clinical condition allows.
Limitations of the study
This study was a single-center, retrospective 
study with potential selection biases. After coro-
nary angiography, the further treatment decisions 
to perform PCI or CABG was at the operator or 
Heart Team discretion. The results of SYNTAX 
score and EuroScore were not available. Mul-
tivariate analysis may be biased because of the 
potential effect of confounding predictors that were 
not accessible in this database. A longer period of 
follow-up is required for more complete evaluation 
of PCI and CABG treatment. 
Conclusions
In summary, presented results indicate that 
more than 90% of patients with multivessel CAD 
in the course of NSTE-ACS underwent coronary 
revascularization, of which the vast majority were 
treated by percutaneous intervention. The highest 
morbidity, risk and severe of CAD was observed 
in patients qualified for medical-only treatment. 
Also, medical-only management was related worse 
long-term prognosis in contrast to revasculariza-
tion, which reduces 24-month mortality. In addition 
to known factors associated with higher mortality, 
the use of PCI is an independent factor for im-
proving prognosis of 24-month follow-up. Optimal 
revascularization method in multivessel CAD and 
NSTE-ACS patients requires multicenter and 
randomized trials in the future.
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